Framing: test shared dependencies and usable capacity rather than counting supplier names. FDA’s shortage communications acknowledge that local supply disruption can persist after a national shortage is resolved. National status is therefore not a guarantee of a particular clinic’s access. (fda.gov)
Put to: Erin Fox and Michael Ganio.
Buyer owner: COO and procurement.
Why it matters: The continuity plan should demonstrate a workable alternative for affected patients, not merely name another company.
A good answer should cover:
- Shared ownership, dispensing facilities, upstream sources, carriers and technology dependencies.
- Product- and state-specific acceptance by the fallback partner.
- Available onboarding capacity and the conditions under which it is reserved or withdrawable.
- Prescription, payment, patient-contact and reporting steps needed to activate it.
- How clinical teams prioritise affected patients without procurement improvising treatment changes.
Follow-up scenario: “Our main partner stops accepting prescriptions on Friday. Which patients can the alternative support, by when, and what still prevents activation?” This is a tabletop scenario, not a forecast.
Evidence to request: A dependency map, written fallback acceptance, named contacts and a completed transition exercise. Ask the expert which dependency matters most and why; do not assume every second partner creates equivalent resilience.
Expert quote — reserved: ________________________________________
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize